Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis

Novartis

Status and phase

Completed

Phase 4

Conditions

Prostate Cancer Patients With Bone Metastasis

Treatments

Drug: Zoledronic acid

Study type

Interventional

Funder types

Industry

Identifiers

NCT00237159

CZOL446EDE07

Details and patient eligibility

About

It is the aim of this clinical study to evaluate the skeletal-related event rate and tolerability of zoledronic acid in patients with prostate cancer patients and bone metastases.

Enrollment

284 patients

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Signed informed consent
A histologically confirmed diagnosis of carcinoma of the prostate
Therapy with hormonal treatments (medical or surgical castration)
Patients must have objective evidence of metastatic disease to bone.
Adequate liver function - serum total bilirubin concentration less than 1.5 x upper limit of normal value
ECOG performance status of 0, 1 or 2

Exclusion criteria

Bone pain which requires strong narcotic therapy with centrally acting analgesic agents.
More than 3 bisphosphonate applications in patients history.
Previous Radiation therapy to bone (including therapeutic radioisotopes such as strontium 89) within 3 months prior to Visit 2.
Abnormal renal function as evidenced by

A calculated creatinine clearance < 30 ml/minute. Creatinine clearance (CrCl) is calculated using the Cockcroft-Gault formula:

CrCl= [140-age (years)] x weight (kg) {x 0.85 for female patients} [72 x serum creatinine (mg/dL)]

Corrected (adjusted for serum albumin) serum calcium concentration < 8.0 mg/dl (2.00 mmol/L) or ≥ 12.0 mg/dl (3.00 mmol/L)
Life expectancy < 6 months
Patients with evidence in the six months prior to randomization of severe cardiovascular disease (defined as uncontrolled congestive heart failure), hypertension refractory to treatment, or symptomatic coronary artery disease uncontrolled by treatment
Use of other investigational drugs (drugs not marketed for any indication) within 30 days prior to the date of randomization
Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures.
Recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants)

Other protocol-defined inclusion and exclusion criteria may apply.